2024
Predicting Radiation-Induced Acute Toxicity in Breast Cancer Patients: A Radiogenomic Approach
Wei S, Zhang Y, Sowmiyanarayanan S, Yehia Z, Jan I, Yue N, Haffty B, Nie K. Predicting Radiation-Induced Acute Toxicity in Breast Cancer Patients: A Radiogenomic Approach. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e341. DOI: 10.1016/j.ijrobp.2024.07.752.Peer-Reviewed Original ResearchBreast cancer patientsRadiation dermatitisSide effectsCancer patientsBreast cancer patients treated with radiationRadiogenomic approachCancer patients treated with radiationRadiation-induced acute toxicityPatients treated with radiationRadiomic featuresSingle nucleotide polymorphismsAcute radiation dermatitisBreast-conserving surgeryRadiation side effectsPeripheral blood samplesTotal radiation dosePersonalized treatment strategiesGenetic statusRadiation therapyMammographic patternsRadiomic texture featuresTherapy side effectsClinical parametersRetrospective studyClinical featuresPre-Operative Boost Results in Low Rates of Re-Excision and Reduced Time from Initial Diagnosis to Completion of Local-Regional Treatment in Breast Cancer Patients
Chakraborty M, Sherwani Z, Yehia Z, Ohri N, Cui T, Eladoumikdachi F, Kowzun M, Kumar S, Potdevin L, Toppmeyer D, Haffty B. Pre-Operative Boost Results in Low Rates of Re-Excision and Reduced Time from Initial Diagnosis to Completion of Local-Regional Treatment in Breast Cancer Patients. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: s201-s202. DOI: 10.1016/j.ijrobp.2024.07.2265.Peer-Reviewed Original ResearchBreast-conserving surgeryWhole breast irradiationDuctal carcinoma in situRe-excision ratesProspective phase II clinical trialRate of re-excisionPhase II clinical trialRe-excisionII clinical trialsHypofractionated regimenWound complicationsPre-operativelyDiagnosis to completionTreated with breast-conserving surgeryClinical trialsInitiation of systemic therapyMedian clinical tumor sizeRisk of wound complicationsIncidence of wound complicationsEarly-stage breast cancerLocal-regional treatmentTumor bed boostClinical tumor sizeNode-positive diseaseCompletion of radiationClinical Outcomes in Breast Cancer Patients with Underlying Germline PALB2 Mutations Treated with Radiation
Shalaby A, Jan I, Ohri N, Yehia Z, Toppmeyer D, Haffty B. Clinical Outcomes in Breast Cancer Patients with Underlying Germline PALB2 Mutations Treated with Radiation. International Journal Of Radiation Oncology • Biology • Physics 2024, 120: e331-e332. DOI: 10.1016/j.ijrobp.2024.07.731.Peer-Reviewed Original ResearchBreast-conserving surgeryPALB2 variantsBreast cancer patientsInterpretations of pathogenicityClinical outcomesPathogenic variantsHypo-RTBreast cancer patients treated with radiationCancer patients treated with radiationCancer patientsRisk of radiation toxicitySentinel lymph node dissectionPatients treated with radiationMedical recordsPALB2 pathogenic variantsContralateral breast cancerExternal beam radiationMedian tumor sizeLymph node dissectionSuppression of cancer developmentGrade 2 fibrosisRecurrence 4 monthsMultigene panel testingDNA double-strand break repairDouble-strand break repair
2023
Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA
Jagsi R, Griffith K, Harris E, Wright J, Recht A, Taghian A, Lee L, Moran M, Small W, Johnstone C, Rahimi A, Freedman G, Muzaffar M, Haffty B, Horst K, Powell S, Sharp J, Sabel M, Schott A, El-Tamer M. Omission of Radiotherapy After Breast-Conserving Surgery for Women With Breast Cancer With Low Clinical and Genomic Risk: 5-Year Outcomes of IDEA. Journal Of Clinical Oncology 2023, 42: 390-398. PMID: 38060195, DOI: 10.1200/jco.23.02270.Peer-Reviewed Original ResearchBreast-conserving surgeryIpsilateral breast eventsEndocrine therapyPostmenopausal patientsBreast cancerCrude rateLower riskBreast cancer-specific survival ratesUnifocal invasive breast cancersYears of ETCancer-specific survival ratesStage I breast cancerHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Omission of radiotherapyYounger postmenopausal patientsPatients age 50Primary end pointBreast conserving surgeryGrowth factor receptor 2I breast cancerInvasive breast cancerRecurrence 5 yearsPatients age 65Single-arm trial
2010
Poly(ADP-ribose) polymerase-1 (PARP-1) expression in patients treated with breast-conserving surgery and radiation therapy (BCS+RT).
Goswami J, Goyal S, Wu H, Moran M, Haffty B. Poly(ADP-ribose) polymerase-1 (PARP-1) expression in patients treated with breast-conserving surgery and radiation therapy (BCS+RT). Journal Of Clinical Oncology 2010, 28: 582-582. DOI: 10.1200/jco.2010.28.15_suppl.582.Peer-Reviewed Original Research